In vivo phage display - A discovery tool in molecular biomedicine

Biotechnology Advances

Volumn 31, Issue 8, 2013, Pages 1247-1259

  Bábíčková, Janka ^a,b   Tóthová, Ľubomíra ^a   Boor, Peter ^a,b   Celec, Peter ^a  

^a Physics and Informatics   (Slovakia)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Molecular medicine; Peptide identification; Phage library; Screening; Targeting

Indexed keywords

DRUG DEVELOPMENT; HETEROGENEOUS EXPRESSIONS; HIGH-THROUGHPUT METHOD; METHODOLOGICAL ASPECTS; MOLECULAR MEDICINE; PEPTIDE IDENTIFICATION; PHAGE LIBRARIES; TARGETING;

EXPERIMENTS; PEPTIDES; SCREENING;

DIAGNOSIS;

DRUG DEVELOPMENT; MAPPING; MEDICINE; PEPTIDE; REPRODUCTION; TARGETING;

ANIMALIA;

CELL SURFACE DISPLAY; DRUG DELIVERY SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR IMAGING; MOLECULAR MEDICINE; NEOVASCULARIZATION (PATHOLOGY); PEPTIDE IDENTIFICATION; PEPTIDE LIBRARY; PHAGE LIBRARY; REVIEW; SCREENING; TARGETING;

MOLECULAR MEDICINE; PEPTIDE IDENTIFICATION; PHAGE LIBRARY; SCREENING; TARGETING;

CELL SURFACE DISPLAY TECHNIQUES; DRUG DELIVERY SYSTEMS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR IMAGING; MOLECULAR MEDICINE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY;

EID: 84887997651     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2013.04.004     Document Type: Review

References (125)

1. Akerman M.E., Pilch J., Peters D., Ruoslahti E. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A 2005, 102:2040-2045.
2. Akita N., Maruta F., Seymour L.W., Kerr D.J., Parker A.L., Asai T., et al. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci 2006, 97:1075-1081.
3. Alva A., Slovin S., Daignault S., Carducci M., Dipaola R., Pienta K., et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012, 30:749-757.
4. Arap W., Pasqualini R. The human vascular mapping project. Selection and utilization of molecules for tumor endothelial targeting. Haemostasis 2001, 31:30-31.
5. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
6. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardo-Vila M., Giordano R.J., et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127.
7. Barbas C.F. Recent advances in phage display. Curr Opin Biotechnol 1993, 4:526-530.
8. Barbas C.F., Kang A.S., Lerner R.A., Benkovic S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 1991, 88:7978-7982.
9. Barnhart K.F., Christianson D.R., Hanley P.W., Driessen W.H., Bernacky B.J., Baze W.B., et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 2011, 3:108ra12.
10. Bastien N., Trudel M., Simard C. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology 1997, 234:118-122.
11. Bauerschmitz G.J., Lam J.T., Kanerva A., Suzuki K., Nettelbeck D.M., Dmitriev I., et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002, 62:1266-1270.
12. Bockmann M., Drosten M., Putzer B.M. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 2005, 7:179-188.
13. Brunet E., Chauvin C., Choumet V., Jestin J.L. A novel strategy for the functional cloning of enzymes using filamentous phage display: the case of nucleotidyl transferases. Nucleic Acids Res 2002, 30:e40.
14. Buerkle M.A., Pahernik S.A., Sutter A., Jonczyk A., Messmer K., Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002, 86:788-795.
15. Bussolati B., Grange C., Tei L., Deregibus M.C., Ercolani M., Aime S., et al. Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display. J Mol Med 2007, 85:897-906.
16. Cao Q., Liu S., Niu G., Chen K., Yan Y., Liu Z., et al. Phage display peptide probes for imaging early response to bevacizumab treatment. Amino Acids 2011, 41:1103-1112.
17. Chang D.K., Chiu C.Y., Kuo S.Y., Lin W.C., Lo A., Wang Y.P., et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 2009, 284:12905-12916.
18. Chen Y.P., Shen Y.Y., Guo X., Zhang C.S., Yang W.J., Ma M.L., et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 2006, 24:455-460.
19. Cortese R., Monaci P., Nicosia A., Luzzago A., Felici F., Galfre G., et al. Identification of biologically active peptides using random libraries displayed on phage. Curr Opin Biotechnol 1995, 6:73-80.
20. Corti A., Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 2004, 1028:104-112.
21. Crameri R., Suter M. Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene 1993, 137:69-75.
22. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000, 18:1185-1190.
23. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002, 110:475-482.
24. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., et al. N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J Med Chem 1999, 42:3033-3040.
25. Denby L., Work L.M., Von Seggern D.J., Wu E., McVey J.H., Nicklin S.A., et al. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol Ther 2007, 15:1647-1654.
26. Deramchia K., Jacobin-Valat M.J., Laroche-Traineau J., Bonetto S., Sanchez S., Dos Santos P., et al. By-passing large screening experiments using sequencing as a tool to identify scFv fragments targeting atherosclerotic lesions in a novel in vivo phage display selection. Int J Mol Sci 2012, 13:6902-6923.
27. Deramchia K., Jacobin-Valat M.J., Vallet A., Bazin H., Santarelli X., Sanchez S., et al. In vivo phage display to identify new human antibody fragments homing to atherosclerotic endothelial and subendothelial tissues [corrected]. Am J Pathol 2012, 180:2576-2589.
28. Dias-Neto E., Nunes D.N., Giordano R.J., Sun J., Botz G.H., Yang K., et al. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One 2009, 4:e8338.
29. Domingo-Espin J., Petegnief V., de Vera N., Conchillo-Sole O., Saccardo P., Unzueta U., et al. RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine 2012, 8:1263-1266.
30. Duerr D.M., White S.J., Schluesener H.J. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J Virol Methods 2004, 116:177-180.
31. Eskens F.A., Dumez H., Hoekstra R., Perschl A., Brindley C., Bottcher S., et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003, 39:917-926.
32. Falciani C., Lozzi L., Pini A., Bracci L. Bioactive peptides from libraries. Chem Biol 2005, 12:417-426.
33. Fan X.M., Venegas R., Fey R., van der Heyde H., Bernard M.A., Lazarides E., et al. An in vivo approach to structure activity relationship analysis of peptide ligands. Pharm Res 2007, 24:868-879.
34. Flint P.W., Li Z.B., Lehar M., Saito K., Pai S.I. Laryngeal muscle surface receptors identified using random phage library. Laryngoscope 2005, 115:1930-1937.
35. Fogal V., Zhang L., Krajewski S., Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 2008, 68:7210-7218.
36. Grabowska A.M., Jennings R., Laing P., Darsley M., Jameson C.L., Swift L., et al. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology 2000, 269:47-53.
37. Gregorc V., Santoro A., Bennicelli E., Punt C.J., Citterio G., Timmer-Bonte J.N., et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009, 101:219-224.
38. Gregorc V., Zucali P.A., Santoro A., Ceresoli G.L., Citterio G., De Pas T.M., et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 2010, 28:2604-2611.
39. Hamzeh-Mivehroud M., Mahmoudpour A., Rezazadeh H., Dastmalchi S. Non-specific translocation of peptide-displaying bacteriophage particles across the gastrointestinal barrier. Eur J Pharm Biopharm 2008, 70:577-581.
40. Hariharan S., Gustafson D., Holden S., McConkey D., Davis D., Morrow M., et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007, 18:1400-1407.
41. Hertveldt K., Robben J., Volckaert G. Whole genome phage display selects for proline-rich Boi polypeptides against Bem1p. Biotechnol Lett 2006, 28:1233-1239.
42. Higgins L.M., Lambkin I., Donnelly G., Byrne D., Wilson C., Dee J., et al. In vivo phage display to identify M cell-targeting ligands. Pharm Res 2004, 21:695-705.
43. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
44. Hong H.Y., Choi J.S., Kim Y.J., Lee H.Y., Kwak W., Yoo J., et al. Detection of apoptosis in a rat model of focal cerebral ischemia using a homing peptide selected from in vivo phage display. J Control Release 2008, 131:167-172.
45. Houston P., Goodman J., Lewis A., Campbell C.J., Braddock M. Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett 2001, 492:73-77.
46. Hust M., Frenzel A., Meyer T., Schirrmann T., Dubel S. Construction of human naive antibody gene libraries. Methods Mol Biol 2012, 907:85-107.
47. Jia W.D., Sun H.C., Zhang J.B., Xu Y., Qian Y.B., Pang J.Z., et al. A novel peptide that selectively binds highly metastatic hepatocellular carcinoma cell surface is related to invasion and metastasis. Cancer Lett 2007, 247:234-242.
48. Johns M., George A.J., Ritter M.A. In vivo selection of sFv from phage display libraries. J Immunol Methods 2000, 239:137-151.
49. Kanki S., Jaalouk D.E., Lee S., Yu A.Y., Gannon J., Lee R.T. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol 2011, 50:841-848.
50. Kelly K.A., Nahrendorf M., Yu A.M., Reynolds F., Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol 2006, 8:201-207.
51. Kim D.H., Woods S.C., Seeley R.J. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes 2010, 59:907-915.
52. Kimball K.J., Preuss M.A., Barnes M.N., Wang M., Siegal G.P., Wan W., et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010, 16:5277-5287.
53. Knowles L.M., Malik G., Hood B.L., Conrads T.P., Pilch J. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis 2012, 15:115-129.
54. Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004, 10:625-632.
55. Kolonin M.G., Sun J., Do K.A., Vidal C.I., Ji Y., Baggerly K.A., et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006, 20:979. [-+].
56. Krag D.N., Shukla G.S., Shen G.P., Pero S., Ashikaga T., Fuller S., et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 2006, 66:7724-7733.
57. Krumpe L.R., Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Pept Res Ther 2006, 12:79-91.
58. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002, 8:751-755.
59. Laakkonen P., Akerman M.E., Biliran H., Yang M., Ferrer F., Karpanen T., et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 2004, 101:9381-9386.
60. Laakkonen P., Zhang L.L., Ruoslahti E. Peptide targeting of tumor lymph vessels. Lymphatic continuum revisited 2008, 37-43.
61. Ladner R.C., Sato A.K., Gorzelany J., de Souza M. Phage display-derived peptides as a therapeutic alternatives to antibodies. Drug Discov Today 2004, 9:525-529.
62. Larbanoix L., Burtea C., Laurent S., Van Leuven F., Toubeau G., Vander Elst L., et al. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging 2010, 31:1679-1689.
63. Laverman P., Sosabowski J.K., Boerman O.C., Oyen W.J. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 2012, 39(Suppl. 1):S78-S92.
64. Lee L., Buckley C., Blades M., Panayi G., George A.J., Pitzalis C. Identification of homing peptides specific for human synovium by in vivo phage display selection. Arthritis Res Ther 2003, 5:103.
65. Lee N.K., Kim M.K., Choi J.H., Kim E.B., Lee H.G., Kang S.K., et al. Identification of a peptide sequence targeting mammary vasculature via RPLPO during lactation. Peptides 2010, 31:2247-2254.
66. Lee N.K., Kim H.S., Kim K.H., Kim E.B., Cho C.S., Kang S.K., et al. Identification of a novel peptide ligand targeting visceral adipose tissue via transdermal route by in vivo phage display. J Drug Target 2011, 19:805-813.
67. Li J.W., Zhang Q.Z., Pang Z.Q., Wang Y.C., Liu Q.F., Guo L.R., et al. Identification of peptide sequences that target to the brain using in vivo phage display. Amino Acids 2012, 42:2373-2381.
68. Loi M., Marchio S., Becherini P., Di Paolo D., Soster M., Curnis F., et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010, 145:66-73.
69. Lorusso D., Scambia G., Amadio G., di Legge A., Pietragalla A., De Vincenzo R., et al. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer 2012, 107:37-42.
70. Ludtke J.J., Sololoff A.V., Wong S.C., Zhang G., Wolff J.A. In vivo selection and validation of liver-specific ligands using a new t7 phage peptide display system. Drug Deliv 2007, 14:357-369.
71. Ludtke J.J., Sokoloff A.V., Wong S., Zhang G.F., Strickland D.K., Wolff J.A. Peptide-mediated targeting of hepatocytes via low density lipoprotein receptor-related protein (LRP). Drug Deliv 2009, 16:268-273.
72. Mammoliti S., Andretta V., Bennicelli E., Caprioni F., Comandini D., Fornarini G., et al. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol 2011, 22:973-978.
73. Manegold C., Vansteenkiste J., Cardenal F., Schuette W., Woll P.J., Ulsperger E., et al. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs 2012, 31:175-182.
74. McGuire M.J., Samli K.N., Johnston S.A., Brown K.C. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol 2004, 342:171-182.
75. Meyer A., Auemheimer J., Modlinger A., Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006, 12:2723-2747.
76. Michon I.N., Hauer A.D., von der Thusen J.H., Molenaar T.J.M., van Berkel T.J.C., Biessen E.A.L., et al. Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. Biochim Biophys Acta Mol Cell Res 2002, 1591:87-97.
77. Molenaar T.J.M., Michon I., de Haas S.A.M., van Berkel T.J.C., Kuiper J., Biessen E.A.L. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 2002, 293:182-191.
78. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 2004, 10:2335-2343.
79. Newton J.R., Kelly K.A., Mahmood U., Weissleder R., Deutscher S.L. In vivo selection of phage for the optical Imaging of PC-3 human prostate carcinoma in mice. Neoplasia 2006, 8:772-780.
80. Nicol C.G., Denby L., Lopez-Franco O., Masson R., Halliday C.A., Nicklin S.A., et al. Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett 2009, 583:2100-2107.
81. Noren K.A., Noren C.J. Construction of high-complexity combinatorial phage display peptide libraries. Methods 2001, 23:169-178.
82. Nowakowski G.S., Dooner M.S., Valinski H.M., Mihaliak A.M., Quesenberry P.J., Becker P.S. A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells. Stem Cells 2004, 22:1030-1038.
83. Parhami-Seren B., Viswanathan M., Margolies M.N. Selection of high affinity p-azophenyarsonate Fabs from heavy-chain CDR2 insertion libraries. J Immunol Methods 2002, 259:43-53.
84. Pasqualini R. Vascular targeting with phage peptide libraries. Q J Nucl Med 1999, 43:159-162.
85. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366.
86. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997, 15:542-546.
87. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000, 60:722-727.
88. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
89. Pilch J., Brown D.M., Komatsu M., Jarvinen T.A., Yang M., Peters D., et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A 2006, 103:2800-2804.
90. Pini A., Bracci L. Phage display of antibody fragments. Curr Protein Pept Sci 2000, 1:155-169.
91. Rafii S., Avecilla S.T., Jin D.K. Tumor vasculature address book: Identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell 2003, 4:331-333.
92. Rajotte D., Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999, 274:11593-11598.
93. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998, 102:430-437.
94. Reardon D.A., Nabors L.B., Stupp R., Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008, 17:1225-1235.
95. Robert R., Jacobin-Valat M.J., Daret D., Miraux S., Nurden A.T., Franconi J.M., et al. Identification of human scFvs targeting atherosclerotic lesions: selection by single round in vivo phage display. J Biol Chem 2006, 281:40135-40143.
96. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
97. Samoylova T.I., Smith B.F. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 1999, 22:460-466.
98. Santoro A., Pressiani T., Citterio G., Rossoni G., Donadoni G., Pozzi F., et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010, 103:837-844.
99. Santoro A., Rimassa L., Sobrero A.F., Citterio G., Sclafani F., Carnaghi C., et al. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer 2010, 46:2746-2752.
100. Scaringi C., Minniti G., Caporello P., Enrici R.M. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 2012, 32:4213-4223.
101. Seow Y., Yin H., Wood M.J. Identification of a novel muscle targeting peptide in mdx mice. Peptides 2010, 31:1873-1877.
102. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
103. Srivastava A.S., Chauhan D.P., Carrier E. In utero detection of T7 phage after systemic administration to pregnant mice. Biotechniques 2004, 37:81-83.
104. Srivastava A.S., Kaido T., Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods 2004, 115:99-104.
105. Staquicini F.I., Cardo-Vila M., Kolonin M.G., Trepel M., Edwards J.K., Nunes D.N., et al. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 2011, 108:18637-18642.
106. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:2712-2718.
107. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
108. Suzuki K., Fueyo J., Krasnykh V., Reynolds P.N., Curiel D.T., Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001, 7:120-126.
109. Ueberberg S., Schneider S. Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo. Regul Pept 2010, 160:1-8.
110. Ueberberg S., Meier J.J., Waengler C., Schechinger W., Dietrich J.W., Tannapfel A., et al. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes 2009, 58:2324-2334.
111. Ueberberg S., Deutschbein T., Klein H.H., Dietrich J.W., Akinturk S., Prochnow N., et al. Protection from diabetes development by single-chain antibody-mediated delivery of a NF-kappaB inhibitor specifically to beta-cells in vivo. Am J Physiol Endocrinol Metab 2011, 301:E83-E90.
112. van Rooy I., Cakir-Tascioglu S., Couraud P.O., Romero I.A., Weksler B., Storm G., et al. Identification of peptide ligands for targeting to the blood-brain barrier. Pharm Res 2010, 27:673-682.
113. Vermorken J.B., Guigay J., Mesia R., Trigo J.M., Keilholz U., Kerber A., et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011, 104:1691-1696.
114. Wan X.M., Chen Y.P., Xu W.R., Yang W.J., Wen L.P. Identification of nose-to-brain homing peptide through phage display. Peptides 2009, 30:343-350.
115. Wu M., Pasula R., Smith P.A., Martin W.J. Mapping alveolar binding sites in vivo using phage peptide libraries. Gene Ther 2003, 10:1429-1436.
116. Wu Q.H., Xu J.L., Lu L., Yang Z.X., Tong G.S., Gao H.L., et al. A radiolabeled nonapeptide probe targeting PC-3 cells and bone metastases of prostate cancer in mice. Contrast Media Mol Imaging 2012, 7:223-230.
117. Yan Z., Lu L., Shi J., Bao C., Han W., Wu Y., et al. Expression, refolding, and characterization of GFE peptide-fused human interferon-alpha2a in Escherichia coli. Appl Biochem Biotechnol 2006, 133:149-162.
118. Yang Y., Zizheng W., Tongxin D. Mouse thymus targeted peptide isolated by in vivo phage display can inhibit bioactivity of thymus output in vivo. J Biomol Screen 2008, 13:968-974.
119. Yang P., He J.T., Wang J.W., Hu Y., Yu L., Jin X., et al. Phage display random peptide library for screening the peptides that specifically bind to hepatocellular carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:1806-1808.
120. Yao V.J., Ozawa M.G., Trepel M., Arap W., McDonald D.M., Pasqualini R. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 2005, 166:625-636.
121. Yu C.Y., Yuan Z., Cao Z., Wang B., Qiao C., Li J., et al. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009, 16:953-962.
122. Zhang L.L., Hoffman J.A., Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation 2005, 112:1601-1611.
123. Zhang T., Qu H.Y., Li X.L., Zhao B.Q., Zhou J.P., Li Q.A., et al. Transmembrane delivery and biological effect of human growth hormone via a phage displayed peptide in vivo and in vitro. J Pharm Sci 2010, 99:4880-4891.
124. Zou J., Dickerson M.T., Owen N.K., Landon L.A., Deutscher S.L. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep 2004, 31:121-129.
125. Zurita A.J., Troncoso P., Cardo-Vila M., Logothetis C.J., Pasqualini R., Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004, 64:435-439.